SCHEMBL3528097

SCHEMBL3528097

Cc1ccc(F)c(NC(=O)Nc2ccc(-c3c(C)sc4ccnc(N)c34)cc2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.74
AURKA O14965 3/20 0.60
KIT P10721 8/20 0.59
FLT3 P36888 7/20 0.59
LCK P06239 5/20 0.59
FLT1 P17948 5/20 0.59
TEK Q02763 5/20 0.59
FLT4 P35916 4/20 0.59
CSF1R P07333 4/20 0.59
PDGFRB P09619 4/20 0.59
FGFR1 P11362 3/20 0.59
FGFR3 P22607 3/20 0.59
PDGFRA P16234 2/20 0.59
FGFR2 P21802 1/20 0.59
FGFR4 P22455 1/20 0.59
BLK P51451 4/20 0.58
LYN P07948 3/20 0.58
FYN P06241 2/20 0.58
ABL1 P00519 2/20 0.58
SRC P12931 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3526386 0.89 KDR (0.75) KDRAURKAKITFLT3LCK
SCHEMBL4474093 0.85 KDR (1.00) KDRAURKAKITFLT3LCK
SCHEMBL3532791 0.84 KDR (1.00) KDRAURKAKITFLT3LCK
SCHEMBL3530171 0.83 KDR (0.78) KDRAURKAKITFLT3LCK
SCHEMBL3527518 0.81 KDR (0.82) KDRAURKAKITFLT3LCK
SCHEMBL3531138 0.79 KDR (0.78) KDRAURKAKITFLT3LCK
SCHEMBL4483101 0.76 KDR (0.80) KDRAURKAKITFLT3LCK
SCHEMBL6056915 0.76 KDR (0.52) KDRAURKAKITFLT3LCK
SCHEMBL6384879 0.75 KDR (0.64) KDRAURKAKITFLT3LCK
SCHEMBL4483133 0.75 AURKA (1.00) KDRAURKAKITFLT3LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
EP-1648905-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS Abbott Laboratories (US) 2006-04-26 EP disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
WO-2005010009-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885AURKA 207/4885KIT 188/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKA 207/4885KIT 188/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKA 207/4885KIT 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.